ANASTROZOLE: A guide to liquid anastrozole and where to purchase
22August 22, 2022
Anastrozole is a nonsteroidal aromatase inhibitor that effectively blocks estrogen synthesis in postmenopausal animal test subjects.
According to the data obtained through clinical studies on rats, anastrozole treated breast cancer cells by shrinking them, making it a potential antineoplastic agent. It is widely used in cancer research, particularly in hormone receptor-positive breast cancer studies. Researchers are also investigating anastrozole for its potential in preventing or decelerating the growth of hormone-sensitive breast cancer, particularly in postmenopausal models at risk of developing breast cancer. It may also inhibit androstenedione-induced uterine hypertrophy in sexually immature rats.
It is sold in liquid form in 1mg per ml vials for research and analytical purposes.
WHAT IS ANASTROZOLE AROMATASE INHIBITOR?
Anastrozole is an anti-aromatase hormone that works by blocking estrogen synthesis, effectively inhibiting human placental aromatase. This inhibition is crucial in research studies focusing on hormone receptor-positive breast cancer, as estrogen plays a significant role in the growth of cancer cells in postmenopausal women. By inhibiting estrogen production, anastrozole may help reduce the growth and spread of these cancer cells, making it a valuable tool in cancer research.
It specifically inhibits human placental aromatase with a high degree of selectivity and a low IC50 value, demonstrating its potency and effectiveness in research settings. As a member of the nitrile and triazole families, anastrozole’s chemical structure contributes to its ability to target and inhibit the aromatase enzyme efficiently. Its role in research is pivotal, especially in studies exploring the treatment of advanced breast cancer and the prevention of metastatic breast cancer.
Anastrozole is a research liquid used for hormone therapy studies in rats. It shows great potential in managing breast cancer, offering insights into new therapeutic approaches and enhancing our understanding of cancer’s intrinsic endocrine effects. The research on anastrozole extends beyond cancer treatment, as it is also studied for its potential applications in managing other estrogen-dependent conditions in animal models. Researchers are continually exploring its efficacy and safety, contributing to a broader understanding of its potential benefits and side effects in various medical contexts.
STRUCTURE OF ANASTROZOLE
Molecular Formula: C17H19N5
Molecular weight: 293.4g/mol
CAS number: 120511-73-1
IUPAC name: 2-[3-(2-cyanopropan-2-yl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropanenitrile
Understanding Anastrozole: Uses, Benefits, and Research Applications in Breast Cancer
Anastrozole is a nonsteroidal third-generation aromatase inhibitor. It selectively binds to and reversibly inhibits aromatase, a cytochrome P-450 enzyme complex that interferes with estradiol production in peripheral tissues, including those of the premenopausal ovary, liver, breast, and other fatty tissues.
Because estrogen acts as a growth factor for hormone-dependent breast cancer cells, anastrozole may treat animal test models with breast cancer caused by estrogen.
Anastrozole has a relatively long duration of action, allowing for once-daily dosing. Its elimination half-life is approximately 50 hours. Anastrozole is also used in the treatment of advanced breast cancer that has progressed following tamoxifen therapy.
Mechanism of Action and Uses
Anastrozole is a potent, highly selective aromatase inhibitor that works by inhibiting the enzyme aromatase, which is involved in the production of estrogen in the body. By blocking the production of estrogen, anastrozole reduces the growth of hormone-sensitive breast cancer cells. This makes it particularly effective in treating breast cancer in postmenopausal women with hormone receptor-positive early breast cancer. Additionally, anastrozole is used in the treatment of advanced breast cancer that has progressed following treatment with tamoxifen. By targeting the estrogen production pathway, anastrozole helps to slow down or even shrink the growth of breast cancer cells, providing a crucial tool in the fight against this disease.
Comparison with Other Aromatase Inhibitors
Anastrozole stands out as a third-generation aromatase inhibitor, known for its high selectivity and potency compared to earlier generations of aromatase inhibitors. This increased selectivity allows anastrozole to more effectively reduce estrogen levels, thereby slowing the growth of breast cancer cells. Clinical trials have shown that anastrozole is as effective, if not more so, than tamoxifen, another widely used hormone therapy for breast cancer. These trials have demonstrated that anastrozole not only reduces the risk of breast cancer recurrence but also offers a favorable side effect profile compared to other aromatase inhibitors. This makes anastrozole a preferred choice in many treatment protocols for hormone receptor-positive breast cancer.
Proper Handling and Storage
Proper handling and storage of anastrozole are essential to ensure its effectiveness and integrity in research applications. This compound should be stored in a sealed container at room temperature, protected from moisture and light. Research protocols suggest maintaining the container securely closed in its original packaging and storing it in a location that is inaccessible to unauthorized personnel. By adhering to these guidelines, researchers can maintain the integrity of the substance, ensuring reliable results in their experimental studies.
Research Quantities and Administration
The recommended research quantity of anastrozole is 1 mg per day, administered orally in test subjects. Research protocols indicate administering the compound at consistent times daily, with or without nutritional intake, to maintain uniform blood concentration levels. For test subjects with ingestion difficulties, anastrozole is available in a 1 mg/ml gastric tube liquid form, which can be administered via a gastric tube. Adhering to the prescribed administration protocols is crucial in laboratory settings. Researchers should follow these guidelines meticulously to achieve accurate and reliable results in their experimental work.
Anastrozole: Essential Information for Research and Applications in Postmenopausal Women
Research suggests anastrozole provides the following benefits in animal test subjects:
Functions as an adjunct therapy for hormone receptor-positive early breast cancer in postmenopausal test subjects.
Serves as first-line approach for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer.
Addresses peripheral precocious puberty
Helps balance testosterone levels in infertile male animals
ANASTROZOLE OBSERVED REACTIONS AND JOINT SYMPTOMS
The following reactions have been observed in animal test subjects during anastrozole research:
Decrease in spine and hip bone mineral density (BMD)
Hot flashes
Altered moods including depression
Arthritis and arthralgia
Hypertension
Nausea and vomiting
Rash
Insomnia
Headache
Peripheral edema
Upper respiratory symptoms including coughing, dyspnea, and pharyngitis
It is important for researchers to document all observed reactions in laboratory settings to advance scientific understanding of this compound.
Interactions with Other Compounds
Anastrozole may interact with other substances, including prescription and over-the-counter compounds, vitamins, and herbal supplements. It is essential for research protocols to account for all substances administered to test subjects, including anastrozole, to ensure valid experimental results. Additionally, ethanol administration while conducting anastrozole research may result in adverse interactions. Research personnel should consult relevant literature for information on possible interactions between anastrozole and other compounds. By understanding these potential interactions, researchers can better analyze the substance’s safety profile and ensure the welfare of their test subjects.
LOOKING FOR WHERE TO BUY ANASTROZOLE ONLINE
Loti Labs offers affordable prices that come with quality control reports. We have in-depth customer support and a generous return policy when you buy anastrozole for sale.
contact us today to buy anastrozole online.
Why Choose Loti Labs for Your Anastrozole Needs?
When it comes to purchasing anastrozole liquid for research purposes, choosing a reputable supplier is crucial. Loti Labs stands out as a top choice for researchers due to our commitment to quality and customer satisfaction. Here’s why buying from Loti Labs is the best decision:
Quality Assurance: We provide high-quality anastrozole liquid that meets rigorous standards. Each batch undergoes thorough testing to ensure purity and efficacy, giving researchers confidence in their experimental results.
Competitive Pricing: At Loti Labs, we offer anastrozole at competitive prices without compromising on quality. Our transparent pricing ensures that you get the best value for your investment.
Exceptional Customer Support: Our knowledgeable customer support team is always ready to assist with any inquiries or concerns. Whether you need guidance on product selection or have questions about your order, we are here to help.
Convenient Online Shopping: Our user-friendly website makes it easy to browse and purchase anastrozole liquid online. With secure payment options and fast shipping, you can receive your order quickly and reliably.
Comprehensive Return Policy: We stand by the quality of our products and offer a generous return policy. If you encounter any issues with your purchase, we are committed to resolving them promptly.
By choosing Loti Labs, you are partnering with a trusted supplier dedicated to supporting your research endeavors. Explore our range of research liquids and experience the Loti Labs difference today.
References:
Lønning P (2003). “Clinical pharmacokinetics of aromatase inhibitors and inactivators”. Clinical Pharmacokinetics. 42 (7): 619–31. doi:10.2165/00003088-200342070-00002. PMID 12844324. S2CID 9585901.
Lønning P, Pfister C, Martoni A, Zamagni C (August 2003). “Pharmacokinetics of third-generation aromatase inhibitors”. Seminars in Oncology. 30 (4 Suppl 14): 23–32. doi:10.1016/S0093-7754(03)00305-1. PMID 14513434.
Sanford M, Plosker GL (2008). “Anastrozole: a review of its use in postmenopausal women with early-stage breast cancer”. Drugs. 68 (9): 1319–40. doi:10.2165/00003495-200868090-00007. PMID 18547136.
Chemical Entities of Biological Interest (ChEBI). European Molecular Biology Laboratory. Archived from the original on 2011-09-22. Retrieved 2011-08-14.
“Highlights of Prescribing Information Anastrozole” (PDF). FDA. Retrieved 31 July 2019.
The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
Chen S (1998) Aromatase and breast cancer. Front Biosci 3: d922–d933
